I-Mab Founder Retakes Reins in Latest Shakeup Ahead of Commercialization Phase
Drug maker announces latest senior appointments as investors anticipate regulatory approval for some of its products as early as 2023 Key takeaways Four-year company veteran and CEO Joan Shen to…
RELATED ARTICLES
-
Novel drugs lift Sino Biopharm earnings, easing price-cap pain
1177.HK -
CSPC Pharma taps R&D superstar in quest for new breakout drugs
1093.HK
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
CSPC Pharma weighs up diet drug for bigger bottom line
1093.HK
-
Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
1672.HK
-
Everest reaches new heights on growing drug sales
1952.HK
